Interaction of discoidin domain receptor 1 with a 14-3-3-Beclin-Akt1 complex modulates glioblastoma therapy sensitivity
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
Glioblastoma (GBM) is highly refractory to therapy and associated with poor clinical outcome. Here, we reveal a critical function of the promitotic and adhesion-mediating discoidin domain receptor 1 (DDR1) in modulating GBM therapy resistance. In GBM cultures and clinical samples, we show a DDR1 and GBM stem cell marker co-expression that correlates with patient outcome. We demonstrate that inhibition of DDR1 in combination with radiochemotherapy with temozolomide in GBM models enhances sensitivity and prolongs survival superior to conventional therapy. We identify a 14-3-3-Beclin-1-Akt1 protein complex assembling with DDR1 to be required for prosurvival Akt and mTOR signaling and regulation of autophagy-associated therapy sensitivity. Our results uncover a mechanism driven by DDR1 that controls GBM therapy resistance and provide a rationale target for the development of therapy-sensitizing agents.
Date Issued
2019-03-26
Date Acceptance
2019-02-22
Citation
Cell Reports, 2019, 26 (13), pp.3672-3683
ISSN
2211-1247
Publisher
Elsevier
Start Page
3672
End Page
3683
Journal / Book Title
Cell Reports
Volume
26
Issue
13
Copyright Statement
© 2019 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Publication Status
Published
Date Publish Online
2019-03-26